Skip to main content
ARTL
NASDAQ Life Sciences

Artelo Biosciences' Lead Drug ART26.12 Shows Favorable Metabolism, De-Risking Clinical Development

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.312
Mkt Cap
$4.636M
52W Low
$1.19
52W High
$85.8
52W Position info
10% above low
Off High info
98% below high
Rel. Volume
Market data snapshot near publication time

ARTL is trading near its 52-week low of $1.19 (10% above the low).

Summary

Artelo Biosciences presented positive human metabolite data for its lead drug candidate, ART26.12, demonstrating a low-risk profile with only three low-level metabolites detected, all previously observed in toxicology studies. This positive clinical development news comes amidst significant financial challenges for Artelo, including a recent going concern warning in its Q1 10-Q and a series of highly dilutive financing activities. The favorable drug metabolism characteristics are critical for successful clinical development, as ADME issues are a common cause of drug failures. This data de-risks ART26.12's path forward, potentially simplifying future development, reducing timelines, and lowering costs for the company's lead pain candidate.

At the time of this announcement, ARTL was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.19 to $85.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ARTL - Latest Insights

ARTL
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.19
Real-time Price: $2.15 info
Change: -$1.04 (-33%) info
Market Cap: $1.178M info
ARTL
Sep 23, 2026, 1:46 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $7.84
Real-time Price: $2.15 info
Change: -$5.69 (-73%) info
Market Cap: $1.178M info
ARTL
Sep 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.02
Real-time Price: $2.15 info
Change: -$2.87 (-57%) info
Market Cap: $1.178M info
ARTL
Aug 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.658
Real-time Price: $2.15 info
Change: Reverse Stock Split info
Market Cap: $1.178M info
ARTL
Aug 27, 2026, 8:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.6899
Real-time Price: $2.15 info
Change: Reverse Stock Split info
Market Cap: $1.178M info